# Dermatitis, Atopic trials: 262 new since Nov 2024

Updated November 6, 2026.

262 clinical studies in Dermatitis, Atopic were first posted on ClinicalTrials.gov from November 13, 2024 to November 6, 2026; 175 have an industry sponsor and 152 are recruiting or about to. The newest, NCT07920809, was posted on November 6, 2026: A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis (Haisco Pharmaceutical Group Co., Ltd.).

## The full list

New Dermatitis, Atopic clinical trials: 262 rows for $13.10, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 11 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/dermatitis-atopic

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 262
- Industry sponsored: 175
- Recruiting or not yet: 152
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 262, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07920809 | A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Dermatitis Atopic | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920809) |
| November 6, 2026 | NCT07920783 | A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 124 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920783) |
| November 5, 2026 | NCT07919899 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Sanofi | Phase 3 | Not yet recruiting | Dermatitis Atopic | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919899) |
| November 5, 2026 | NCT07918586 | Localized Aeroallergen Exposure in Atopic Dermatitis | Fraunhofer-Institute of Toxicology and Experimental Medicine | Not applicable | Not yet recruiting | Atopic Dermatitis | 15 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918586) |
| November 5, 2026 | NCT07918560 | Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis | Brainfarma Industria Química e Farmacêutica S/A | Not applicable | Not yet recruiting | Atopic Dermatitis, Psoriasis | 42 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918560) |
| November 4, 2026 | NCT07916480 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Recruiting | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 415 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916480) |
| November 3, 2026 | NCT07914088 | A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis | Arjil Pharmaceuticals LLC | Phase 2 | Recruiting | Dermatitis Atopic | 40 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914088) |
| November 2, 2026 | NCT07909967 | Observational Analytical Validation Study of the Replior ScratchSense | Replior AB | Observational | Recruiting | Atopic Dermatitis, Pruritus, Chronic Pruritus of Unknown Origin | 35 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909967) |
| October 29, 2026 | NCT07905547 | A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | Sanofi | Phase 4 | Not yet recruiting | Atopic Dermatitis | 56 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905547) |
| October 29, 2026 | NCT07904689 | A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis | North Immunology Inc. | Phase 1 | Not yet recruiting | Atopic Dermatitis (AD) | 96 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904689) |
| October 29, 2026 | NCT07904546 | ADBest TREAT Registry | Universitätsklinikum Hamburg-Eppendorf | Observational | Recruiting | Atopic Dermatitis | 5,000 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904546) |
| October 26, 2026 | NCT07895615 | Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic... | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895615) |
| October 21, 2026 | NCT07887867 | A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | Pfizer | Observational | Not yet recruiting | Dermatitis, Atopic | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887867) |
| October 14, 2026 | NCT07873801 | A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis | Almirall, S.A. | Phase 3 | Not yet recruiting | Atopic Dermatitis | 230 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873801) |
| October 2, 2026 | NCT07856134 | AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | Forefront Dermatology S.C | Phase 4 | Not yet recruiting | Atopic Dermatitis | 250 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856134) |
| September 29, 2026 | NCT07848074 | Abrocitinib Dose Tapering in Patients With Atopic Dermatitis | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | Not yet recruiting | Atopic Dermatitis | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848074) |
| September 28, 2026 | NCT07843290 | A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis | Guangzhou JOYO Pharma Co., Ltd | Phase 2 | Not yet recruiting | Atopic Dermatitis (AD) | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843290) |
| September 25, 2026 | NCT07842900 | Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis | Can Tho University of Medicine and Pharmacy | Not applicable | Not yet recruiting | Atopic Dermatitis | 130 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842900) |
| September 24, 2026 | NCT07839897 | EFFICACY AND TOLERANCE OF AN EMOLLIENT CREAM IN SKIN OF COLOR | Pierre Fabre Dermo Cosmetique | Not applicable | Completed | Atopic Dermatitis (AD) | 59 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839897) |
| September 16, 2026 | NCT07823595 | Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age | Pfizer | Phase 3 | Not yet recruiting | Atopic Dermatitis | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823595) |
| September 14, 2026 | NCT07819071 | EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS | Pierre Fabre Dermo Cosmetique | Not applicable | Completed | Atopic Dermatitis (AD) | 33 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819071) |
| September 10, 2026 | NCT07813611 | Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis | Istanbul Medeniyet University | Observational | Not yet recruiting | Atopic Dermatitis (AD), Scabies, Impetigo | 51 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813611) |
| September 9, 2026 | NCT07810777 | PRA-216 Atopic Dermatitis Safety and Efficacy Study | Prana Therapies Inc | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 39 | Australia, New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810777) |
| September 8, 2026 | NCT07807228 | Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment | University Hospital Bispebjerg and Frederiksberg | Observational | Recruiting | Atopic Dermatitis | 60 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807228) |
| September 4, 2026 | NCT07804134 | Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in... | Medisch Spectrum Twente | Observational | Not yet recruiting | Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS) | 1,000 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804134) |
| September 2, 2026 | NCT07800104 | Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis | QuantX Biosciences, Inc. | Phase 1 | Recruiting | Atopic Dermatitis | 84 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800104) |
| August 25, 2026 | NCT07784816 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 2/3 | Not yet recruiting | Atopic Dermatitis (AD) | 390 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784816) |
| August 24, 2026 | NCT07783425 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema | Pfizer | Phase 3 | Recruiting | Atopic Dermatitis | 1,375 | Canada, Japan, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783425) |
| August 24, 2026 | NCT07782476 | Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis | Helixon Biotechnology (Suzhou) Co., Ltd | Phase 1/2 | Not yet recruiting | Health Adult Subjects, Atopic Dermatitis (AD) | 67 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782476) |
| August 24, 2026 | NCT07782333 | A Study Evaluating TRIV-573 in Atopic Dermatitis | Triveni Bio | Phase 2 | Recruiting | Atopic Dermatitis | 90 | Canada, Ukraine, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782333) |
| August 17, 2026 | NCT07767253 | Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Dermatitis, Atopic | 246 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767253) |
| August 14, 2026 | NCT07765888 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema | Pfizer | Phase 3 | Recruiting | Atopic Dermatitis | 375 | Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765888) |
| August 13, 2026 | NCT07762833 | Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | Galderma R&D | Phase 3 | Recruiting | Atopic Dermatitis | 240 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762833) |
| August 10, 2026 | NCT07754968 | Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Without Atopic Dermatitis | University of Roma La Sapienza | Not applicable | Recruiting | Infant Colic, Atopic Dermatitis | 64 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754968) |
| August 10, 2026 | NCT07754786 | A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 520 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754786) |
| August 5, 2026 | NCT07748169 | An Observational Study of Patients With Dermatologic Disease | Target PharmaSolutions, Inc. | Observational | Not yet recruiting | Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS) | 2,000,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748169) |
| August 5, 2026 | NCT07746817 | A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis | Bionyra Pharma | Phase 1 | Recruiting | Atopic Dermatitis, Healthy Participants | 56 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746817) |
| August 5, 2026 | NCT07746427 | Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis | Weill Medical College of Cornell University | Not applicable | Recruiting | Atopic Dermatitis, Eczema | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746427) |
| August 4, 2026 | NCT07744516 | Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis | Laboratorios Ozoaqua | Not applicable | Completed | Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 50 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744516) |
| August 3, 2026 | NCT07742241 | Efficacy Study of a Repairing Cream in Atopic Dermatitis | Instituto de Investigacion Biotecnologica, Farmaceutica y Medicamentos Huerfanos, S.L. | Not applicable | Completed | Atopic Dermatitis (AD) | 116 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742241) |
| August 3, 2026 | NCT07741838 | Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic... | AbbVie | Observational | Not yet recruiting | Atopic Dermatitis | 900 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741838) |
| July 29, 2026 | NCT07734415 | Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis | Inmagene LLC | Phase 2 | Enrolling by invitation | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema | 400 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734415) |
| July 28, 2026 | NCT07730788 | Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab | Hôpitaux Drôme Nord | Observational | Recruiting | Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 15 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730788) |
| July 20, 2026 | NCT07713186 | Azithromycin in Atopic Dermatitis | Cairo University | Phase 4 | Not yet recruiting | Atopic Dermatitis | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713186) |
| July 14, 2026 | NCT07703215 | NPQ Plus Supplementation for Skin Health and Antioxidant Status | N REMEDIER (M) SDN BHD | Not applicable | Completed | Eczema, Atopic Dermatitis, Skin Health, Fatigue Symptom, Sleep Quality, Antioxidant Capacity, Oxidative Stress | 55 | Malaysia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703215) |
| July 14, 2026 | NCT07701447 | Efficacy and Tolerability of a Probiotic Ointment | BioGaia AB | Not applicable | Not yet recruiting | Atopic Dermatitis | 92 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701447) |
| July 14, 2026 | NCT07700745 | A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin | Rejuvaskin | Not applicable | Active not recruiting | Eczema, Atopic Dermatitis, Eczema-Prone Skin | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700745) |
| July 13, 2026 | NCT07698756 | A Clinical Study of HRS-8797 in Healthy Participants | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 74 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698756) |
| July 9, 2026 | NCT07693400 | Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis | Taiwan Municipal An-Nan Hospital-China Medical University | Phase 2 | Active not recruiting | Atopic Dermatitis (AD) | 44 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693400) |
| July 6, 2026 | NCT07684937 | HL-300 Ointment in Healthy Volunteers | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 1 | Completed | Atopic Dermatitis | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684937) |
| July 1, 2026 | NCT07678645 | The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | RenJi Hospital | Phase 2 | Not yet recruiting | Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD) | 44 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678645) |
| June 26, 2026 | NCT07670676 | The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With Eczema | Codex Labs Corporation | Not applicable | Completed | Atopic Dermatitis (Eczema) | 40 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670676) |
| June 23, 2026 | NCT07661979 | Opzelura Experience Study | Wake Forest University Health Sciences | Phase 4 | Not yet recruiting | Atopic Dermatitis | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661979) |
| June 22, 2026 | NCT07659756 | Global Healthcare Study on Atopic Dermatitis | Julia Tatjana Maul | Observational | Recruiting | Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 9,600 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659756) |
| June 17, 2026 | NCT07653386 | Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis | VinUniversity | Not applicable | Completed | Mild and Moderate Atopic Dermatitis Patients, Atopic Dermatitis (AD) | 90 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653386) |
| June 12, 2026 | NCT07645820 | Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares | Castle Biosciences Incorporated | Observational | Recruiting | Atopic Dermatitis | 450 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645820) |
| June 12, 2026 | NCT07643766 | A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis | Enveda Therapeutics | Phase 2 | Recruiting | Atopic Dermatitis | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643766) |
| June 5, 2026 | NCT07629778 | HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 1/2 | Recruiting | Atopic Dermatitis | 156 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629778) |
| June 1, 2026 | NCT07618234 | Dermocosmetic Evaluation of Propolis Ointments in Atopic-Prone Dry Skin | Manara University | Not applicable | Completed | Dry Skin, Atopic Dermatitis, Xerosis Due to Atopic Dermatitis | 30 | Syria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618234) |
| May 29, 2026 | NCT07613190 | Adjunctive Oral Iron Supplementation in Atopic Dermatitis | Cairo University | Not applicable | Not yet recruiting | Atopic Dermatitis | 124 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613190) |
| May 22, 2026 | NCT07604324 | A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to... | Novartis Pharmaceuticals | Phase 1 | Recruiting | Dermatitis, Atopic | 63 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604324) |
| May 20, 2026 | NCT07599878 | Adjunctive Group Psychotherapy for Moderate-to-Severe Atopic Dermatitis: A Pilot Feasibility Study Comparing Two Interventions | Semmelweis University | Not applicable | Completed | Atopic Dermatitis | 32 | Hungary | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599878) |
| May 20, 2026 | NCT07599813 | A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | Apollo Therapeutics Ltd | Phase 2 | Recruiting | Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis... | 280 | Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599813) |
| May 20, 2026 | NCT07598383 | A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in... | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Recruiting | Atopic Dermatitis | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598383) |
| May 18, 2026 | NCT07592585 | Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Atopic Dermatitis | 360 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592585) |
| May 12, 2026 | NCT07582237 | Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106) | Kang Stem Biotech Co., Ltd. | Observational | Active not recruiting | Dermatitis, Atopic | 262 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582237) |
| May 11, 2026 | NCT07577921 | Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments | Pierre Fabre Dermo Cosmetique | Observational | Completed | Atopic Dermatitis | 80 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577921) |
| May 7, 2026 | NCT07574242 | Effect of vitk2 on Atopic Dermatitis Pediatrics Patients | October 6 University | Not applicable | Completed | Atopic Dermatitis | 100 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574242) |
| May 7, 2026 | NCT07573735 | Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis | Zhongda Hospital | Observational | Recruiting | Atopic Dermatitis (Eczema) | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573735) |
| May 6, 2026 | NCT07568665 | Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy. | Hôpitaux Drôme Nord | Observational | Active not recruiting | Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 15 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07568665) |
| May 1, 2026 | NCT07560618 | Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical... | Integrative Skin Science and Research | Phase 4 | Recruiting | ITCH, Atopic Dermatitis | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560618) |
| April 30, 2026 | NCT07559773 | The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Model to Optimize Maternal and Infant Health | GrowBaby Life Project | Not applicable | Not yet recruiting | Preterm Birth, Preeclampsia, Gestational Diabetes Mellitus (GDM), Small for Gestational Age (SGA), Large for... | 500 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559773) |
| April 24, 2026 | NCT07550452 | Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to... | Peking University People's Hospital | Not applicable | Not yet recruiting | Atopic Dermatitis (AD) | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550452) |
| April 24, 2026 | NCT07549984 | A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 16 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549984) |
| April 24, 2026 | NCT07549828 | Sebum Metabolomics and Lipidomics for Clinical Applications | National Taiwan University Hospital | Not applicable | Not yet recruiting | Acne, Atopic Dermatitis, Seborrheic Dermatitis, Psoriasis, Healthy Subjects (HS) | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549828) |
| April 24, 2026 | NCT07549750 | A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants | Helixon Biotechnology (Suzhou) Co., Ltd | Phase 1 | Not yet recruiting | Atopic Dermatitis | 28 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549750) |
| April 22, 2026 | NCT07544862 | A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD) | Chengdu Kangnuoxing Biopharma,Inc. | Observational | Recruiting | Atopic Dermatitis (AD) | 1,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544862) |
| April 20, 2026 | NCT07540442 | A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Not yet recruiting | Dermatitis, Atopic | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540442) |
| April 17, 2026 | NCT07537751 | Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis | Noura Abdelmoneim Mohammed Elseessy | Not applicable | Completed | Atopic Dermatitis, Eczema | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537751) |
| April 16, 2026 | NCT07533851 | A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Atopic Dermatitis | 31 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533851) |
| April 14, 2026 | NCT07527923 | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Healthy Volunteer, Atopic Dermatitis | 160 | Belgium, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527923) |
| April 13, 2026 | NCT07525505 | Nigella Sativa Oil for Eczematous Otitis Externa | Bezmialem Vakif University | Not applicable | Recruiting | Eczema/Atopic Dermatitis, Otitis Externa | 85 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525505) |
| April 9, 2026 | NCT07519174 | A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With... | Foundation University Islamabad | Not applicable | Not yet recruiting | Atopic Dermatitis | 72 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519174) |
| March 31, 2026 | NCT07503197 | A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis | Institute of Dermatology, Thailand | Not applicable | Enrolling by invitation | Atopic Dermatitis (AD), Cholesterol, Skin Barrier to Water Loss, Skin Allergy, Eczema Atopic Dermatitis, Trans... | 30 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503197) |
| March 23, 2026 | NCT07488065 | A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Atopic Dermatitis | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488065) |
| March 23, 2026 | NCT07487831 | The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease | University of California, San Francisco | Phase 4 | Recruiting | Atopic Dermatitis (Eczema), Psoriasis | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487831) |
| March 18, 2026 | NCT07479615 | A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis, Atopic Eczema | 498 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479615) |
| March 12, 2026 | NCT07467564 | The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis | Sanofi | Observational | Recruiting | Atopic Dermatitis | 184 | Qatar, Saudi Arabia, United Arab Emirates | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07467564) |
| March 12, 2026 | NCT07466940 | A Clinical Study to Evaluate SM17 in Healthy Participants | SinoMab BioScience Ltd | Phase 1 | Completed | Atopic Dermatitis, Asthma, Inflammatory Bowel Disease | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466940) |
| March 6, 2026 | NCT07455578 | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | Seismic Therapeutic AU Pty Ltd | Phase 1 | Recruiting | Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus... | 24 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455578) |
| March 6, 2026 | NCT07453602 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | Arcutis Biotherapeutics, Inc. | Phase 1 | Recruiting | Atopic Dermatitis (AD), Eczema | 125 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453602) |
| March 4, 2026 | NCT07448363 | Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica | Caja Costarricense de Seguro Social | Observational | Not yet recruiting | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients, Atopic Dermatitis /... | 50 | Costa Rica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448363) |
| March 3, 2026 | NCT07447063 | The Impact of Dietary Salt on the Severity of Eczema | University of California, San Francisco | Phase 4 | Recruiting | Eczema, Atopic Dermatitis | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447063) |
| March 3, 2026 | NCT07445919 | A Clinical Study to Evaluate SM17 for Atopic Dermatitis | SinoMab BioScience Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07445919) |
| March 3, 2026 | NCT07444801 | Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact | University Hospital Schleswig-Holstein | Observational | Recruiting | Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region | 30 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444801) |
| March 2, 2026 | NCT07444008 | Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete | NovoNatum Ltd | Not applicable | Recruiting | Infantile Colics, Constipation, Infantile Diarrhea, Atopic Dermatitis | 140 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444008) |
| March 2, 2026 | NCT07441395 | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Corvus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441395) |
| February 27, 2026 | NCT07438509 | Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema | Jinnah Postgraduate Medical Centre | Phase 4 | Not yet recruiting | Atopic Dermatitis (AD), Atopic Eczema | 270 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07438509) |
| February 27, 2026 | NCT07437534 | Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical... | Hayat Abad Medical Complex, Peshawar | Phase 4 | Not yet recruiting | Atopic Dermatitis | 148 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07437534) |
| February 25, 2026 | NCT07434076 | Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine | Shanghai Yueyang Integrated Medicine Hospital | Observational | Not yet recruiting | Psoriasis, Atopic Dermatitis | 950 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434076) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Pfizer | 11 | October 21, 2026 |
| Pierre Fabre Dermo Cosmetique | 9 | September 24, 2026 |
| Sanofi | 7 | November 5, 2026 |
| Jiangsu vcare pharmaceutical technology co., LTD | 6 | May 20, 2026 |
| Innovent Biologics (Suzhou) Co. Ltd. | 4 | August 10, 2026 |
| Cairo University | 4 | July 20, 2026 |
| Codex Labs Corporation | 4 | June 26, 2026 |
| Shanghai Mabgeek Biotech.Co.Ltd | 4 | April 20, 2026 |
| University of California, San Francisco | 4 | March 23, 2026 |
| Keymed Biosciences Co.Ltd | 4 | November 17, 2025 |
| Arcutis Biotherapeutics, Inc. | 3 | November 4, 2026 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 3 | September 29, 2026 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | 3 | August 25, 2026 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 3 | August 17, 2026 |
| AbbVie | 3 | August 3, 2026 |
| Enveda Therapeutics | 3 | June 12, 2026 |
| Novartis Pharmaceuticals | 3 | May 22, 2026 |
| SinoMab BioScience Ltd | 3 | March 12, 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 | December 4, 2025 |
| Akeso | 3 | January 10, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 58 | November 5, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 55 | November 3, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 48 | November 2, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 46 | November 6, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 30 | November 5, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 16 | October 29, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 5 | August 24, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 3 | August 25, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 1 | July 3, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 68 | November 4, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 67 | November 6, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 29 | August 24, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 26 | September 14, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 22 | November 5, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 16 | November 2, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 16 | August 24, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 15 | August 4, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 14 | October 29, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 14 | August 10, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 12 | January 22, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 10 | May 20, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 9 | May 20, 2026 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 8 | September 9, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 7 | November 5, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 7 | November 3, 2026 |
| [Bulgaria](https://specstream.ai/data/clinical-trials/country/bulgaria) | 6 | May 20, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 5 | July 20, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 5 | November 17, 2025 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 4 | May 12, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 4 | April 14, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 3 | September 8, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 3 | September 4, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 3 | April 9, 2026 |
| [Thailand](https://specstream.ai/data/clinical-trials/country/thailand) | 3 | March 31, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).